Intersect ENT (XENT) Stock Price, News & Analysis

Company Overview

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Key Stats

• Today's Range: $28.24 to $28.24
• 50-Day Range: $28.24 to $28.24
• 52-Week Range: $15.92 to $28.25
• Volume: 14,512 shs
• Average Volume: 351,526 shs
• Market Capitalization: $954.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XENT Stock Analysis - Frequently Asked Questions

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.06. The medical equipment provider earned $24.40 million during the quarter, compared to the consensus estimate of $29.63 million. Intersect ENT had a negative trailing twelve-month return on equity of 709.52% and a negative net margin of 161.94%.

What other stocks do shareholders of Intersect ENT own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG) and Air Transport Services Group (ATSG).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:XENT
• CIK: 1271214
• Web: www.intersectent.com
• Phone: (650) 641-2100
• Fax: 866-736-1251
• Employees: 433
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$159.63 million
• Net Margins: -161.94%
• Pretax Margin: -163.16%
• Return on Equity: -709.52%
• Return on Assets: -48.18%

Debt

• Debt-to-Equity Ratio: 6.89
• Current Ratio: 1.88
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $106.75 million
• Price / Sales: 8.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.06) per share
• Price / Book: -13.71

Miscellaneous

• Outstanding Shares: 33,814,000
• Free Float: 33,104,000
• Market Cap: $954.91 million
• Optionable: Optionable
• Beta: 1.45